Scrip Pharma Intelligence

January 4, 2023
Scrip Asks…What Does 2023 Hold For Biopharma? Part 1: The Funding Environment

“I expect that we will see more flat or down rounds with private life science companies in early 2023 as companies get to the end of their cash runway and need additional funding to take them to data catalysts. Many of these rounds will likely be insider rounds with existing investors. Once we see the IPO market re-open, which I expect will happen in H2 2023, then we will likely see more money start to flow into both public and private life science companies and we will start to see valuations increase,” said James Mackay, CEO of Aristea Therapeutics, Inc. read more →


December 13, 2022
Pharma people on the move: Fall 2022 roundup

San Diego-based Aristea Therapeutics has appointed three experienced drug development experts to key positions. Himanshu Patel, D.O., is executive medical director; Jennifer Barnes, Ph.D., is senior director, clinical science; and Walter Frank Eng, Pharm.D., is associate director, clinical science. read more →


December 12, 2022
The 2023 PharmaVoice Year in Preview

A look at how industry leaders are navigating the key issues of 2023. read more →

NPR BioTech Nation with Dr. Moira Gunn

December 4, 2022
22-47 Dr. James Mackey, President & CEO, Aristea Therapeutics

Too much of a good thing spells trouble - in this case, that would be neutrophils – the white blood cells that act as our immune system’s first line of defense. It's called PPP, or Palmoplantar Pustulosis. Dr. James Mackey is the President & CEO of Aristea Therapeutics. read more →

Life Science Leader

December 2, 2022
2023 Finance And Funding Outlook: Additional Insights Part 1

Biopharma’s have been in a fundraising recession for over a year which has forced many to already begin making tough choices... read more →

BioSpace (Alex Keown)

November 4, 2022
Movers & Shakers

San Diego-based Aristea bolstered its clinical operations team with three appointments. Himanshu Patel was named executive medical director; Jennifer Barnes was named senior director of clinical science; and Walter Frank Eng was named associate director of clinical science. read more →

Fierce Biotech (Max Bayer, Gabrielle Masson)

November 4, 2022
Chutes & Ladders

Immunology company Aristea Therapeutics has appointed three new leaders in positions that will guide drug development. read more →

BioCentury (Richard Guy)

November 2, 2022
Cox to head digital health at Pfizer

read more →


November 2, 2022
Appointments and advancements for Nov. 2, 2022

New hires and promotions in the biopharma industry, including: Actinium, Ambrx, Anebulo, Aristea... read more →

Life Science Leader

November 1, 2022
Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

San Diego-based Aristea Therapeutics, spun out of AstraZeneca in 2018 and led by founder, president, and CEO James Mackay, is less than one year away from a clinical trial read-out that could change the company’s trajectory, as well as advance a new drug candidate into late-stage trials for a rare disease with no approved products on the market. read more →

Endpoints News

August 26, 2022
No Myth: CEO of ADC upstart calls it quits; Bristol Myers vet Jon Wigginton scales new heights at Bright Peak

Now partnering with Pfizer on an old AstraZeneca drug named RIST4721 after initially striking the deal with Arena last summer, Aristea Therapeutics has added Poseida Therapeutics CEO Mark Gergen and Novo Ventures partner Daniel O’Connell to the board of read more →


August 24, 2022
Appointments and advancements for Aug. 24, 2022

Aristea Therapeutics Inc., of San Diego, added Mark Gergen and Daniel O'Connell to its board. Michael Vincent joins as a board observer. read more →

Empowered Patient Podcast

August 2, 2022
Treating Inflammatory Diseases by Blocking Neutrophils Moving from Bone Marrow

James Mackay is the Founder, President, and CEO of Aristea Therapeutics, a San Diego-based company that is applying its insights on neutrophils to develop a treatment for a rare inflammatory skin condition known as palmoplantar pustulosis, PPP. Most of the people who get this disease are postmenopausal females, and 90%+ of the patients either are current cigarette smokers or have a history of cigarette smoking. read more →

Tech Nation Radio Podcast

July 15, 2022
Tech Visionary – No Tech

Dr. James Mackey, the President & CEO, Aristea Therapeutics, tells about a painful disease which affects the palms of hand and soles of feet in post-menopausal women - Palmoplantar pustulosis or PPP - and how it may relate to other diseases. read more →

Clinical Trials Arena

July 14, 2022
Aristea contemplates Phase III design for rare skin disease drug

As Aristea develops a palmoplantar pustulosis treatment, US and European regulators indicate different primary endpoint preferences. read more →

Pharmaceutical Executive

July 8, 2022
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs

COVID-19 pandemic, the challenging capital-markets climate in biotech, and a more innovative and specialty treatment focus has increased reliance on the finance arm as a key strategic cog. read more →


July 5, 2022
Aristea Therapeutics in four clinical trials in rare inflammatory diseases

Closely-held Aristea Therapeutics is pursuing four rare inflammatory diseases with its oral, once-daily, small molecule drug candidate, RIST4721: palmoplantar pustulosis, familial Mediterranean fever, Behcet's disease and hidradenitis suppurativa. read more →

Rheumatology Network

June 10, 2022
Familial Mediterranean Fever: Minimizing Inflammation and Preventing Flares

Nihar Bhakta, MD, explains Familial Mediterranean Fever, a rare rheumatic disease, and how Aristea Therapeutics is working to treat patients suffering from this condition. read more →

Two Disabled Dudes Podcast

May 15, 2022
Doing the Right Thing with James Mackay, CEO Aristea Tx

James Mackay, PhD, Founder, President and Chief Executive Officer of Aristea Therapeutics, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. James joins The Dudes to discuss his experience and how he is contributing to the biotech leadership community. read more →


April 4, 2022
Clinical Catch-Up: Adagio to Seek COVID-19 EUA, CytoDyn’s Bad Week

It was a particularly busy week for clinical trial announcements. read more →


March 18, 2022
Targeting Rare, Immunologic Disorders

Aristea Therapeutics was spun out of AstraZeneca to develop medicines for rare, immunologic disorders. Its lead program in development is an experimental therapy for a rare skin condition that causes repeated outbreaks of painful pustules on the hands and feet and is being looked at for other neutrophil-mediated diseases. We spoke to James Mackay, president and CEO of Aristea, about the decision to form the company, its lead therapy in development, and its collaboration and development deal with Arena Pharmaceuticals that gives its partner an option to acquire it outright. read more →


March 9, 2022
COVID-19 Changed the Biopharma Industry – and There’s No Going Back

As the COVID-19 pandemic approaches its second anniversary in North America, the medical industry looks much different than it did just two years ago. Health and safety protocols have changed drastically, economies are still shifting and political tensions have heightened as a result of restrictions put in place to manage the virus. read more →

Finding Genius Podcast

March 6, 2022
Drug Development for Inflammatory Disease and the Research Surrounding Gout Therapeutics with Nihar Bhakta

Why has Gout been an incredibly challenging condition for many individuals to treat? Even though treatments have been developed and used, Gout flares can remain, being an incredibly painful and diminishing quality of life. Listen to learn. read more →

CFO Dive

February 23, 2022
First-time biotech CFO strategizes for future with or without big pharma

Since taking over as finance chief of the small biotech company Aristea Therapeutics Inc. last year, first-time CFO Justin Thacker has stretched into his new strategic responsibilities to help prepare the company for a range of scenarios, including a public offering. read more →

Biotech 2050 Podcast

February 16, 2022
From pharma to founding a biotech, James Mackay, Founder, President & CEO, Aristea Therapeutics

James Mackay, PhD, Founder, President and Chief Executive Officer, has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. read more →

Finding Genius Podcast

February 10, 2022
Palmoplantar Pustulosis Symptoms and the Causes and Treatments for Inflammatory Skin Diseases with James Mackay

What makes palmoplantar pustulosis symptoms so difficult to treat? Based on its unique makeup, relief can be challenging to find. Listen to learn. read more →


January 24, 2022
Aristea is Rehoming Proven Molecules for Rare Inflammatory Diseases

Aristea Therapeutics is on a rescue mission. The San Diego-based immunology company is using its considerable expertise and experience to locate and develop molecules where the mechanism of action has either been proven or makes sense. read more →

Clinical OMICs

December 14, 2021
Pfizer Acquires Arena for $6.7B To Improve Immuno-Inflammatory Offering

Pfizer will acquire Arena Pharmaceuticals in a deal worth $6.7 billion to expand its pipeline of immuno-inflammatory disease drugs in development. read more →

Genetic Engineering & Biotechnology News

December 13, 2021
Pfizer to Acquire Arena for $6.7B, Expanding Immuno-Inflammatory Pipeline

Pfizer has agreed to acquire Arena Pharmaceuticals for approximately $6.7 billion, the companies said today, in a deal designed to expand the buyer’s immuno-inflammatory disease pipeline, led by Arena’s Phase II/II lead candidate etrasimod. read more →

Rare Disease, Cell & Gene Therapy Monthly RoundUp

November 30, 2021
Special episode featuring James Mackay – November 2021

James provides insights on his experience with setting up a biotech and challenges associated, industry climate on spin off opportunities, Aristea’s pipeline, collaborations and US PRMA reforms. read more →


October 6, 2021
Interview with Aristea Therapeutics CEO James Mackay

Aristea is developing drugs for inflammatory diseases, starting with palmoplantar pustulosis. James shares his journey from small town Scotland to big pharma and San Diego. read more →


September 20, 2021
It’s a New Hybrid World for Biopharma

The hybrid workplace is here, and by most accounts, biopharmas - medium and small - appear to be embracing it. read more →

Outsourced Pharma

September 8, 2021
Do You Understand The Motives of Your Advisors?

Over two previous editorials, James Mackay, Aristea Therapeutics CEO, and experienced independent board member to emerging biopharma organizations, has explained his role as an advisor to CEOs and member of governing boards, most particularly as it relates to the outsourcing function. read more →

Outsourced Pharma

September 1, 2021
How Involved Should Biopharma CEOs Be In Outsourcing Activities?

James Mackay, CEO of Aristea Therapeutics, and independent board member to emerging biopharma, says when he's advising new CEOs, he answers by first informing them at some point along the way... read more →

Endpoints News

August 27, 2021
AstraZeneca promotes oncology exec to CMO; Pfizer replaces retiring chief dealmaker as war chest expands

San Diego-based Aristea Therapeutics has tapped Justin Thacker as CFO. read more →


August 27, 2021
BioSpace Movers & Shakers, Aug. 27

Biopharma companies and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers. read more →

Fierce Biotech

August 27, 2021
Chutes & Ladders—Pfizer taps McKinsey U.S. managing partner as new M&A leader

Justin Thacker joined immunology biotech Aristea Therapeutics as chief financial officer. read more →


August 24, 2021
Appointments and advancements for Aug. 23, 2021

New hires and promotions in the biopharma industry, including: Aristea... read more →

Genetic Engineering & Biotechnology News

August 16, 2021
Wider Arena: Aristea Pursues Excellence with $123M in Investment

Collaboration with San Diego neighbor Arena Pharma, and a $63-million Series B propel development of drug cast off by AstraZeneca, says CEO James Mackay read more →

Outsourced Pharma

August 11, 2021
An Independent Board Member Advises Emerging Biopharma On Outsourcing

What exactly is an independent board member? read more →

Life Science Leader

July 30, 2021
Back to the Office

Since lockdowns that began mid-Mar. 2020, remote work became the new norm for many, along with a new perspective. From the boardroom down to entry-level positions, knowledge workers suddenly saw their work and personal lives in a completely new light. read more →

San Diego Metro

July 29, 2021
Daily Business Report: Thursday, July 29, 2021

Aristea Therapeutics, a San Diego clinical-stage immunology-focused drug development company developing novel therapies to treat serious inflammatory orphan diseases, announced the closing of a $63 million Series B financing. read more →

Endpoints News

July 28, 2021
AstraZeneca castoff draws $128M wager on CXCR2 antagonist as Arena lines up a buyout option

Back in 2018, James Mackay — then leading an inflammatory disease group at AstraZeneca after leading the pharma giant’s acquisition of Ardea — took interest in a drug that’d been relegated to the shelves four years earlier. read more →


July 28, 2021
Arena Pharma In-Licenses Aristea’s CXCR2 Antagonist For Immune-Mediated Inflammatory Disease

Arena Pharmaceuticals Inc and Aristea Therapeutics Inc have collaborated to develop RIST4721 for palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. read more →

The Pharma Letter

July 28, 2021
Arena inks deal with Aristea for RIST4721 and acquisition option 

US companies Arena Pharmaceuticals and Aristea Therapeutics have entered into a strategic collaboration. read more →

Fierce Biotech

July 28, 2021
Arena taps Aristea in $70M inflammation deal, secures buyout option

Arena Pharmaceuticals is ponying up $60 million upfront and investing $10 million in Aristea Therapeutics to collaborate on the latter’s inflammatory disease program and snag the option to acquire its partner. read more →


July 28, 2021
Financings for July 28, 2021

Biopharmas raising money in public or private financings, including: Aristea read more →


July 28, 2021
Other news to note for July 28, 2021

Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief. read more →


July 27, 2021
Money on the Move: July 21 – 27, 2021

A quick overview of life science companies scooping up some summer spending money this week including: Aristea. read more →

Seeking Alpha 

July 27, 2021
Arena Pharmaceuticals and Aristea ink RIST4721 collaboration agreement

Arena Pharmaceuticals (NASDAQ:ARNA) and Aristea Therapeutics announce a strategic collaboration to advance the clinical development of RIST4721, an oral CXCR2 antagonist being developed by Aristea for the treatment of palmoplantar pustulosis (PPP) and other neutrophil-mediated diseases. read more →


July 27, 2021
Aristea plots path forward in rare skin disease with $63M series B, Arena deal

Arena obtains option to acquire well-funded AZ spinout after palmoplantar pustulosis readout. read more →

BioPharma Dive

July 27, 2021
An AstraZeneca spinout scores a buyout option from Arena

Arena Pharmaceuticals has paid $60 million for an option to acquire Aristea Therapeutics, a private biotech founded in 2018 to develop an experimental inflammatory drug discovered by AstraZeneca. read more →